Neuropeptide Y-based recombinant peptides ameliorate bone loss in mice by regulating hematopoietic stem/progenitor cell mobilization

BMB Rep. 2017 Mar;50(3):138-143. doi: 10.5483/bmbrep.2017.50.3.191.

Abstract

Ovariectomy-induced bone loss is related to an increased deposition of osteoclasts on bone surfaces. We reported that the 36-amino-acid-long neuropeptide Y (NPY) could mobilize hematopoietic stem/progenitor cells (HSPCs) from the bone marrow to the peripheral blood by regulating HSPC maintenance factors and that mobilization of HSPCs ameliorated low bone density in an ovariectomy-induced osteoporosis mouse model by reducing the number of osteoclasts. Here, we demonstrated that new NPY peptides, recombined from the cleavage of the full-length NPY, showed better functionality for HSPC mobilization than the full-length peptide. These recombinant peptides mediated HSPC mobilization with greater efficiency by decreasing HSPC maintenance factors. Furthermore, treatment with these peptides reduced the number of osteoclasts and relieved ovariectomy-induced bone loss in mice more effectively than treatment with full-length NPY. Therefore, these results suggest that peptides recombined from full-length NPY can be used to treat osteoporosis. [BMB Reports 2017; 50(3): 138-143].

MeSH terms

  • Animals
  • Bone Marrow / metabolism
  • Bone Marrow Cells / metabolism
  • Disease Models, Animal
  • Granulocyte Colony-Stimulating Factor / metabolism
  • Hematopoietic Stem Cell Mobilization / methods*
  • Hematopoietic Stem Cells / metabolism
  • Humans
  • Mice
  • Neuropeptide Y / metabolism*
  • Neuropeptide Y / therapeutic use*
  • Osteoclasts / metabolism
  • Osteoporosis
  • Osteoporosis, Postmenopausal / therapy*
  • Ovariectomy / adverse effects

Substances

  • Neuropeptide Y
  • Granulocyte Colony-Stimulating Factor